Search

Your search keyword '"Massari, Francesco"' showing total 17 results
Start Over Author "Massari, Francesco" Journal cancers
17 results on '"Massari, Francesco"'

2. Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System

Author

Raschi, Emanuel, primary, Fusaroli, Michele, additional, Giunchi, Valentina, additional, Repaci, Andrea, additional, Pelusi, Carla, additional, Mollica, Veronica, additional, Massari, Francesco, additional, Ardizzoni, Andrea, additional, Poluzzi, Elisabetta, additional, Pagotto, Uberto, additional, and Di Dalmazi, Guido, additional

Published
2022
Full Text
View/download PDF

3. Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study

Author

Rizzo, Alessandro, primary, Mollica, Veronica, additional, Marchetti, Andrea, additional, Nuvola, Giacomo, additional, Rosellini, Matteo, additional, Tassinari, Elisa, additional, Molina-Cerrillo, Javier, additional, Myint, Zin W., additional, Buchler, Tomas, additional, Monteiro, Fernando Sabino Marques, additional, Grande, Enrique, additional, Santoni, Matteo, additional, and Massari, Francesco, additional

Published
2022
Full Text
View/download PDF

4. Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives

Author

Rebuzzi, Sara Elena, primary, Rescigno, Pasquale, additional, Catalano, Fabio, additional, Mollica, Veronica, additional, Vogl, Ursula Maria, additional, Marandino, Laura, additional, Massari, Francesco, additional, Pereira Mestre, Ricardo, additional, Zanardi, Elisa, additional, Signori, Alessio, additional, Buti, Sebastiano, additional, Bauckneht, Matteo, additional, Gillessen, Silke, additional, Banna, Giuseppe Luigi, additional, and Fornarini, Giuseppe, additional

Published
2022
Full Text
View/download PDF

5. PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?

Author

Marchetti, Andrea, primary, Rosellini, Matteo, additional, Nuvola, Giacomo, additional, Tassinari, Elisa, additional, Mollica, Veronica, additional, Rizzo, Alessandro, additional, Santoni, Matteo, additional, Cimadamore, Alessia, additional, Farolfi, Andrea, additional, Montironi, Rodolfo, additional, Fanti, Stefano, additional, and Massari, Francesco, additional

Published
2022
Full Text
View/download PDF

7. Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough

Author

Mollica, Veronica, primary, Brocchi, Stefano, additional, Dall’Olio, Filippo Gustavo, additional, Marcolin, Laura, additional, Paccapelo, Alexandro, additional, Santoni, Matteo, additional, Rizzo, Alessandro, additional, Montironi, Rodolfo, additional, Golfieri, Rita, additional, Massari, Francesco, additional, and Ardizzoni, Andrea, additional

Published
2021
Full Text
View/download PDF

9. Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art

Author

Mollica, Veronica, primary, Rizzo, Alessandro, additional, Rosellini, Matteo, additional, Marchetti, Andrea, additional, Ricci, Angela Dalia, additional, Cimadamore, Alessia, additional, Scarpelli, Marina, additional, Bonucci, Chiara, additional, Andrini, Elisa, additional, Errani, Costantino, additional, Santoni, Matteo, additional, Montironi, Rodolfo, additional, and Massari, Francesco, additional

Published
2021
Full Text
View/download PDF

11. Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma

Author

Mollica, Veronica, primary, Rizzo, Alessandro, additional, Montironi, Rodolfo, additional, Cheng, Liang, additional, Giunchi, Francesca, additional, Schiavina, Riccardo, additional, Santoni, Matteo, additional, Fiorentino, Michelangelo, additional, Lopez-Beltran, Antonio, additional, Brunocilla, Eugenio, additional, Brandi, Giovanni, additional, and Massari, Francesco, additional

Published
2020
Full Text
View/download PDF

12. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

Author

Santoni, Matteo, primary, Heng, Daniel Y., additional, Bracarda, Sergio, additional, Procopio, Giuseppe, additional, Milella, Michele, additional, Porta, Camillo, additional, Matrana, Marc R., additional, Cartenì, Giacomo, additional, Crabb, Simon J., additional, De Giorgi, Ugo, additional, Basso, Umberto, additional, Masini, Cristina, additional, Calabrò, Fabio, additional, Vitale, Maria Giuseppa, additional, Santini, Daniele, additional, Massari, Francesco, additional, Galli, Luca, additional, Fornarini, Giuseppe, additional, Ricotta, Riccardo, additional, Buti, Sebastiano, additional, Zucali, Paolo, additional, Caffo, Orazio, additional, Morelli, Franco, additional, Carrozza, Francesco, additional, Martignetti, Angelo, additional, Gelibter, Alain, additional, Iacovelli, Roberto, additional, Mosca, Alessandra, additional, Atzori, Francesco, additional, Vau, Nuno, additional, Incorvaia, Lorena, additional, Ortega, Cinzia, additional, Scarpelli, Marina, additional, Lopez-Beltran, Antonio, additional, Cheng, Liang, additional, Paolucci, Vittorio, additional, Graham, Jeffrey, additional, Pierce, Erin, additional, Scagliarini, Sarah, additional, Sepe, Pierangela, additional, Verzoni, Elena, additional, Merler, Sara, additional, Rizzo, Mimma, additional, Sorgentoni, Giulia, additional, Conti, Alessandro, additional, Piva, Francesco, additional, Cimadamore, Alessia, additional, Montironi, Rodolfo, additional, and Battelli, Nicola, additional

Published
2019
Full Text
View/download PDF

13. Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers

Author

Santoni, Matteo, primary, Cimadamore, Alessia, additional, Massari, Francesco, additional, Piva, Francesco, additional, Aurilio, Gaetano, additional, Martignetti, Angelo, additional, Scarpelli, Marina, additional, Di Nunno, Vincenzo, additional, Gatto, Lidia, additional, Battelli, Nicola, additional, Cheng, Liang, additional, Lopez-Beltran, Antonio, additional, and Montironi, Rodolfo, additional

Published
2019
Full Text
View/download PDF

14. Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor

Author

Mollica, Veronica, primary, Di Nunno, Vincenzo, additional, Gatto, Lidia, additional, Santoni, Matteo, additional, Scarpelli, Marina, additional, Cimadamore, Alessia, additional, Lopez-Beltran, Antonio, additional, Cheng, Liang, additional, Battelli, Nicola, additional, Montironi, Rodolfo, additional, and Massari, Francesco, additional

Published
2019
Full Text
View/download PDF

15. The Human Microbiota and Prostate Cancer: Friend or Foe?

Author

Massari, Francesco, primary, Mollica, Veronica, additional, Di Nunno, Vincenzo, additional, Gatto, Lidia, additional, Santoni, Matteo, additional, Scarpelli, Marina, additional, Cimadamore, Alessia, additional, Lopez-Beltran, Antonio, additional, Cheng, Liang, additional, Battelli, Nicola, additional, Montironi, Rodolfo, additional, and Brandi, Giovanni, additional

Published
2019
Full Text
View/download PDF

17. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.

Author

Santoni, Matteo, Heng, Daniel Y., Bracarda, Sergio, Procopio, Giuseppe, Milella, Michele, Porta, Camillo, Matrana, Marc R., Cartenì, Giacomo, Crabb, Simon J., De Giorgi, Ugo, Basso, Umberto, Masini, Cristina, Calabrò, Fabio, Vitale, Maria Giuseppa, Santini, Daniele, Massari, Francesco, Galli, Luca, Fornarini, Giuseppe, Ricotta, Riccardo, and Buti, Sebastiano

Subjects
ANTINEOPLASTIC agents, CONFIDENCE intervals, HEMOGLOBINS, MEDICAL cooperation, METASTASIS, MULTIVARIATE analysis, RENAL cell carcinoma, RESEARCH, STATISTICS, SURVIVAL analysis (Biometry), TIME, PROPORTIONAL hazards models, RETROSPECTIVE studies, DESCRIPTIVE statistics, KAPLAN-Meier estimator, ODDS ratio
Abstract

Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second- or third-line cabozantinib. A multicenter retrospective real-world study was conducted, involving 32 worldwide centers. A total of 237 patients with histologically confirmed clear-cell and non-clear-cell RCC who received cabozantinib as second- or third-line therapy for metastatic disease were included. We analyzed overall survival (OS), progression-free survival (PFS) and time-to-strategy failure (TTSF) using Kaplan–Meier curves. Cox proportional models were used at univariate and multivariate analyses.The median PFS and OS of cabozantinib were 7.76 months (95% CI 6.51–10.88) and 11.57 months (95% CI 10.90–not reached (NR)) as second-line and 11.38 months (95% CI 5.79–NR) and NR (95% CI 11.51–NR) as third-line therapy. The median TTSF and OS were 11.57 and 15.52 months with the sequence of cabozantinib–nivolumab and 25.64 months and NR with nivolumab–cabozantinib, respectively. The difference between these two sequences was statistically significant only in good-risk patients. In the second-line setting, hemoglobin (Hb) levels (HR= 2.39; 95% CI 1.24–4.60, p = 0.009) and IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) group (HR = 1.72, 95% CI 1.04–2.87, p = 0.037) were associated with PFS while ECOG-PS (HR = 2.33; 95%CI, 1.16–4.69, p = 0.018) and Hb levels (HR = 3.12; 95%CI 1.18–8.26, p = 0.023) correlated with OS at multivariate analysis, while in the third-line setting, only Hb levels (HR = 2.72; 95%CI 1.04–7.09, p = 0.042) were associated with OS. Results are limited by the retrospective nature of the study.This real-world study provides evidence on the presence of prognostic factors in RCC patients receiving cabozantinib. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results